| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9954465 | Lung Cancer | 2018 | 7 Pages |
Abstract
Evidence suggests first-line pembrolizumab for NSCLC may be cost-effective in the US but not the UK, in spite of very similar ICER values in both countries.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mina Georgieva, Joao P. da Silveira Nogueira Lima, Pedro Jr., Gilberto Jr., Benjamin Haaland,